Evaluation of the Effect of Wet Cupping (Hijama) on Primary Fibromyalgia
Key facts
- Where
- Cairo, EgyptSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT06320262, who can take part
Where in Egypt
- Rheumatology and Immunology out patient clinic, Internal Medicine Department, Cairo UniversityCairo, EgyptContact: Rasmia MH ElgoharyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Rasmia Elgohary
- Trial code
- NCT06320262
- Record updated
- 30 December 2024
- Original description
Fibromyalgia has become one of the most prevalent chronic pain conditions that impair quality of life. Wet cupping has gained increasing popularity in treating painful conditions.Read full original descriptionShow less
Evaluation of the Effect of Wet Cupping (Hijama) on Primary Fibromyalgia Using Brain Magnetic Resonance Spectroscopy and Patient-reported Forms: Randomized Controlled Clinical Trial
Fibromyalgia has become one of the most prevalent chronic pain conditions that impair quality of life. Wet cupping has gained increasing popularity in treating painful conditions.
This study aims to investigate the effectiveness of wet cupping therapy combined with home-based exercise compared to home-based exercise alone in improving patients diagnosed with primary fibromyalgia syndrome.
Inclusion: Adult patients aged 18-55 years; Female individuals to avoid the gender confounding factor; Clinical diagnosis of primary fibromyalgia according to the 2016 American College of Rheumatology (ACR) updated diagnostic criteria; Moderate pain intensity of ≥ 45 mm or higher on a visual analog scale (VAS); No use of skeletal muscle relaxants, antidepressants, antiepileptic drugs, corticosteroids, benzodiazepines, and tramadol within a year before the screening visit.
Exclusion: Patients with bleeding disorders or receiving anticoagulants; Previous use, within a year, or current use of skeletal muscle relaxants, antidepressants, antiepileptic drugs, corticosteroids, benzodiazepines, or tramadol; Underlying rheumatic, malignant, metabolic, hematological, or neurological disorders; Patients with BMI ≤ 18 or ≥ 35; Pregnant or lactating women; Patients with severe anemia.